All In Biotech

Drug Trial Radar · NCT01363388

A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment

Last checked: Nov 20, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

Sep 2011

Primary completion

Oct 2015

Study completion Jan 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to optimize the treatment to induce remission for patients with non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV). The intent is to reduce the toxicity of induction therapy by reducing the overall exposure to or eliminating entirely the use of systemic corticosteroids during the induction period with an inhibitor of the complement C5a receptor plus cyclophosphamide or rituximab.

Conditions

  • Vasculitis

Interventions

  • PlaceboDrug

    BID for 84 days

  • CCX168Drug

    BID for 84 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects Achieving Disease Response at Day 85Time frame: Baseline to Day 85

Locations

44 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Feldkirch, Austria

  • Site not named

    Innsbruck, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Edegem, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Prague, Czechia

  • Site not named

    Bordeaux, France

  • Site not named

    Boulogne-sur-Mer, France

  • Site not named

    Brest, France

  • Site not named

    Colmar, France

  • Site not named

    Grenoble, France

  • Site not named

    Nantes, France

  • Site not named

    Paris, France

  • Site not named

    Saint-Jacques, France

  • Site not named

    Valenciennes, France

  • Site not named

    Berlin, Germany

  • Site not named

    Cologne, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Freiburg im Breisgau, Germany

  • Site not named

    Fulda, Germany

  • Site not named

    Heidelberg, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Groningen, Netherlands

  • Site not named

    Leiden, Netherlands

  • Site not named

    Rotterdam, Netherlands

  • Site not named

    Utrecht, Netherlands

  • Site not named

    Bialystok, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Szczecin, Poland

  • Site not named

    Wroclaw, Poland

  • Site not named

    Linköping, Sweden

  • Site not named

    Lund, Sweden

  • Site not named

    Malmö, Sweden

  • Site not named

    Stockholm, Sweden

  • Site not named

    Birmingham, United Kingdom

  • Site not named

    Cambridge, United Kingdom

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.